AF solution
Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Cancer-associated fibroblasts (CAFs) play a crucial role in the microenvironment of cancer.
These cells are present within and/or around cancer lesions, and in cancer types where CAFs are concentrated, there is often a low response to anticancer drugs.
Additionally, the maintenance of a CAF-centric cancer microenvironment can lead to a higher likelihood of recurrence, even if there is a tumor destruction effect.
We have established a method for isolating CAFs, defined co-culture conditions for CAFs and organoids (including cell ratios and culture medium composition), and validated the ability to evaluate drug responses to immunotherapeutic agents.
Cancer Associate Fibroblast(CAF)
Pancreatic cancer organoids are a sophisticated model system that faithfully reproduces the complexity of
patient tumors.
Retaining tumor heterogeneity, genetic features, and tissue architecture, they provide valuable insights into drug responses, personalized disease modeling, and disease progression.
These organoids play a crucial role in identifying biomarkers, conducting high-throughput drug screening, and incorporating the tumor microenvironment for a comprehensive understanding of pancreatic cancer biology.
Overall, they stand as a potent tool in advancing research and developing personalized treatment strategies
for pancreatic cancer.
Cancer-Associated Fibroblasts(CAFs) play a crucial role in the evaluation of anticancer drugs.
They modulate the cancer environment, making it challenging for anticancer drugs to infiltrate and limiting treatment effectiveness.
Additionally, they regulate immune responses, restricting the efficacy of anticancer immunotherapy.
Moreover, CAFs promote cancer invasion and metastasis, potentially inducing resistance to anticancer drugs.
Considering these functions of CAFs is crucial for accurately assessing the efficacy of anticancer drugs and developing strategies to address these challenges.
at 72 hours after Gemcitabine treatment
When co-administered with a drug that enhances drug permeability, Gemcitabine sensitivity is increased.
The CIPCO model recreates the physical environment surrounding cancer cells, reproducing drug permeability in patient cancer tissues.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
